



Heart Failure with Preserved Ejection Fraction.

The SGLT-2 inhibitor empagliflozin, sacubitril/valsartan, and spironolactone have been demonstrated to be effective in subsets of patients with HFpEF. Attention to renal function, and avoidance of use in patients with eGFR <30 is guideline based for empagliflozin and spironolactone. Sacubitril/valsartan can be prescribed when the eGFR is <30 at ½ the usual recommended starting dose. Cardiology consultation should be considered.

Charles F. Lovell, Jr., MD, FACP
November 15, 2021